Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 12/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953665 | 0.96 | MKNK1 (0.47) | MKNK1MKNK2CYP11B2 | |
| SCHEMBL7953705 | 0.89 | CYP2C9 (0.43) | MKNK1MKNK2CYP11B2HDAC3HDAC1 | |
| SCHEMBL7946664 | 0.88 | CYP11B2 (0.43) | CYP11B2HDAC3HDAC1HDAC2CYP2C9 | |
| Hydrochloric Acid SCHEMBL10742608 | 0.87 | CYP2C9 (0.39) | CYP11B2HDAC3HDAC1HDAC2GAA | |
| SCHEMBL7946521 | 0.85 | KMO (0.46) | MKNK1MKNK2CYP11B2GAACYP2C9 | |
| SCHEMBL7954905 | 0.85 | NR4A2 (0.46) | CYP11B2 | |
| SCHEMBL10742663 | 0.85 | MKNK1 (0.45) | MKNK1MKNK2CYP11B2HDAC3HDAC1 | |
| SCHEMBL7946362 | 0.85 | CDC7 (0.50) | CYP11B2GAACYP2C9 | |
| Hydrochloric Acid SCHEMBL10737389 | 0.83 | CYP11B2 (0.41) | MKNK1MKNK2CYP11B2CYP2C9 | |
| SCHEMBL10858691 | 0.81 | MKNK1 (0.45) | MKNK1MKNK2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361253-A1 | COMPOUNDS | Selcia Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| WO-2010029364-A1 | COMPOUNDS | SELCIA LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998025612-A1 | NOVEL THERAPEUTIC APPLICATION OF PYRROLE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |
| US-4584297-A | Pyrrolo[1,2-c]-1,3-thiazines | RHONE-POULENC SANTE (FR) | 1986-04-22 | — | — | US | disclosed |
| US-4546100-A | Pyrrolo[1,2-c]thiazoles useful as antithrombotic agents | RHONE-POULENC SANTE (FR) | 1985-10-08 | — | — | US | disclosed |
| US-4539400-A | Pyridin-3-yl substituted ortho-fused pyrrole derivatives | RHONE-POULENC SANTE (FR) | 1985-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | MKNK1 3856/4885MKNK2 3481/4885CYP11B2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.